EUVIMEDEUVIMED entdecken
Open Access

Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles

Andrew S Choi, Taylor J Moon, Anubhuti Bhalotia, Aarthi Rajan, Laolu Ogunnaike, Diarmuid W Hutchinson, Inga Hwang, Aaditya Gokhale, Justin N Kim, Timothy Ma, Efstathios Karathanasis iD

Molecular Pharmaceutics · 07.04.2025 · 22 (4) · 1859-1868

DOI: 10.1021/acs.molpharmaceut.4c01039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 04.03.2025. Verfasst von Andrew S Choi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, United States. Hauptthemen laut MEDLINE: Polyethylene Glycols, Nanoparticles, Immune Checkpoint Inhibitors, Lipids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIBIB NIH HHS, National Science Foundation Graduate Research Fellowship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The engineerability of lipid nanoparticles (LNPs) and their ability to deliver nucleic acids make LNPs attractive tools for cancer immunotherapy. LNP-based gene delivery can be employed for various approaches in cancer immunotherapy, including encoding tumor-associated antigens and silencing of negative immune checkpoint proteins. For example, LNPs carrying small interfering RNAs can offer several advantages, including sustained and durable inhibition of an immune checkpoint protein. Due to their tunable design, modifying the lipid composition of LNPs can regulate the rate of their uptake by immune cells and the rate of gene silencing. Controlling the kinetics of LNP uptake provides additional flexibility and strategies to generate appropriate immunomodulation in the tumor microenvironment. Here, we evaluated the effects of polyethylene glycol (PEG) content ranging from 0.5 to 6 mol % on the cellular uptake of LNPs by immune cells and gene silencing of PD-L1 after intratumoral administration. We evaluated the cellular uptake and PD-L1 blockade in vitro in cell studies and in vivo using the YUMM1.7 melanoma tumor model. Cell studies showed that the rate of cell uptake was inversely correlated to an increasing mol % of PEG in a linear relationship. In the in vivo studies, 0.5% PEG LNP initiated an immediate effect in the tumor with a significant decrease in the PD-L1 expression of immune cells observed within 24 h. In comparison, the gene silencing effect of 6% PEG LNP was delayed, with a significant decrease of PD-L1 expression in immune cell subsets being observed 72 h after administration. Notably, performance of the 6% PEG LNP at 72 h was comparable to that of the 0.5% PEG LNP at 24 h. Overall, this study suggests that PEG modifications and intratumoral administration of LNPs can be a promising strategy for an effective antitumor immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsNanoparticlesImmune Checkpoint InhibitorsLipidsAnimalsMiceCell Line, TumorB7-H1 AntigenHumansRNA, Small InterferingImmunotherapyTumor MicroenvironmentFemaleGene SilencingLiposomes

Stichwörter der Autor:innen

PD-L1PEGimmune checkpoint inhibitorlipid nanoparticlesmelanoma

Substanzen

Polyethylene GlycolsImmune Checkpoint InhibitorsB7-H1 AntigenRNA, Small InterferingLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, United States.

ORCID-Profile: Efstathios Karathanasis

Förderung

  • NCI NIH HHS
  • NIBIB NIH HHS
  • National Science Foundation Graduate Research Fellowship Program
  • National Cancer Institute
  • Case Western Reserve University

Zitieren

APA

Choi, A. S., Moon, T. J., Bhalotia, A., Rajan, A., Ogunnaike, L., Hutchinson, D. W., Hwang, I., Gokhale, A., Kim, J. N., Ma, T., & Karathanasis, E. (2025). Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles. Molecular Pharmaceutics, 22(4), 1859-1868. https://doi.org/10.1021/acs.molpharmaceut.4c01039

Vancouver

Choi AS, Moon TJ, Bhalotia A, Rajan A, Ogunnaike L, Hutchinson DW, et al. Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles. Molecular Pharmaceutics. 2025;22(4):1859-1868. doi:10.1021/acs.molpharmaceut.4c01039

BibTeX
@article{Choi2025,
  author = {Choi, Andrew S and Moon, Taylor J and Bhalotia, Anubhuti and Rajan, Aarthi and Ogunnaike, Laolu and Hutchinson, Diarmuid W and Hwang, Inga and Gokhale, Aaditya and Kim, Justin N and Ma, Timothy and Karathanasis, Efstathios},
  title = {Lipid Nanoparticles and PEG: Time Frame of Immune Checkpoint Blockade Can Be Controlled by Adjusting the Rate of Cellular Uptake of Nanoparticles},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {4},
  pages = {1859--1868},
  doi = {10.1021/acs.molpharmaceut.4c01039}
}
Kostenlos starten →